Mangalam Drugs And Organics Limited has informed the Exchange about General Updates
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mangalam Drugs and Organics Limited has received a repeat export order from an international client valued at USD 21,81,040 (approximately ₹18-19 crore at current exchange rates). The order is to be executed over the next 2-4 months. The company clarified that the awarding entity has no connection to its promoters or group companies, and the transaction is not a related party deal. The disclosure was made under SEBI's Listing Regulation 30 as a material event, since the order size is significant compared to ordinary business activity. The company highlighted that this order strengthens its presence in the global pharmaceutical market and supports revenue visibility in upcoming quarters.
Positive for shareholders — the repeat order signals continued trust from an existing overseas client and adds near-term revenue visibility. Since the order is a one-time export contract (not a long-term deal), its impact is more on quarterly earnings than long-term valuation, but it reinforces the company's export-driven growth story.